Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 5/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.59 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.54 |
| ▸ | GP6 | Q9HCN6 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584496 | 0.87 | SLC22A12 (0.77) | SLC22A12CYSLTR2CYSLTR1KMT2AXDH | |
| SCHEMBL1248713 | 0.81 | SLC22A12 (0.68) | SLC22A12CYSLTR2CYSLTR1XDHGP6 | |
| SCHEMBL13113060 | 0.77 | XDH (0.85) | SLC22A12CYSLTR2CYSLTR1XDHGP6 | |
| SCHEMBL1233637 | 0.76 | SLC22A12 (0.62) | SLC22A12CYSLTR2CYSLTR1KMT2AALDH1A1 | |
| SCHEMBL13113378 | 0.73 | GP6 (0.68) | SLC22A12CYSLTR2CYSLTR1XDHGP6 | |
| SCHEMBL12367 | 0.72 | GP6 (0.66) | SLC22A12XDHGP6IDO1ALDH1A1 | |
| SCHEMBL31234168 | 0.71 | XDH (0.57) | SLC22A12CYSLTR2CYSLTR1XDHGP6 | |
| SCHEMBL1250957 | 0.70 | FFAR1 (0.58) | SLC22A12CYSLTR2CYSLTR1KMT2AGP6 | |
| SCHEMBL1628598 | 0.69 | GP6 (0.66) | SLC22A12KMT2AXDHGP6IDO1 | |
| SCHEMBL10066157 | 0.68 | TP53 (0.65) | SLC22A12KMT2AXDHGP6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282736-B1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8889724-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130336949-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-19 | — | — | US | disclosed |
| US-8410154-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2282736-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009134995-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130336949-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | GLS, CASP1, PCSK9 | SLC22A12 637/4885CYSLTR2 2404/4885CYSLTR1 1790/4885 |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | FPR1, CASP1, PON1 | SLC22A12 1227/4885CYSLTR2 2838/4885CYSLTR1 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.